Ribavirin and Interferon Therapy for Critically Ill Patients with Middle East Respiratory Syndrome: A Multicenter Observational Study

Clinical Infectious Diseases

Volumn 70, Issue 9, 2020, Pages 1837-1844

  Arabi, Yaseen M ^a   Shalhoub, Sarah ^b,c   Mandourah, Yasser ^d   Al Hameed, Fahad ^e   Al Omari, Awad ^f   Qasim, Eman Al ^b   Jose, Jesna ^b   Alraddadi, Basem ^g,h   Almotairi, Abdullah ⁱ   Khatib, Kasim Al ^j   Abdulmomen, Ahmed ^k   Qushmaq, Ismael ^g   Sindi, Anees A ^l   Mady, Ahmed ^m,n   Solaiman, Othman ^g   Al Raddadi, Rajaa ^o   Maghrabi, Khalid ^g   Ragab, Ahmed ^p   Mekhlafi, Ghaleb A Al ^q   Balkhy, Hanan H ^a   Harthy, Abdulrahman Al ^m   Kharaba, Ayman ^r   Gramish, Jawaher A ^s   Al Aithan, Abdulsalam M ^t   Al Dawood, Abdulaziz ^a   Merson, Laura ^u   Hayden, Frederick G ^u,v   Fowler, Robert ^w   more..

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b WESTERN UNIVERSITY   (Canada)

^c KING FAHD ARMED FORCES HOSPITAL   (Saudi Arabia)

^d Defense Ministry   (Saudi Arabia)

^e KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^f ALFAISAL UNIVERSITY   (Saudi Arabia)

^g KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^h UNIVERSITY OF JEDDAH   (Saudi Arabia)

ⁱ KING FAHAD MEDICAL CITY   (Saudi Arabia)

^j AL NOOR SPECIALIST HOSPITAL   (Saudi Arabia)

^k KING SAUD UNIVERSITY   (Saudi Arabia)

^l King Abdulaziz University   (Saudi Arabia)

^m Riyadh Regional Laboratory   (Saudi Arabia)

ⁿ TANTA UNIVERSITY HOSPITAL   (Egypt)

^o KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^p KING FAHAD GENERAL HOSPITAL   (Saudi Arabia)

^q Prince Sultan Military Medical City   (Saudi Arabia)

^r KING FAHAD HOSPITAL   (Saudi Arabia)

^s KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^t King Abdul Aziz Hospital   (Saudi Arabia)

^u UNIVERSITY OF OXFORD   (United Kingdom)

^v UNIVERSITY OF VIRGINIA   (United States)

^w UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Coronavirus; Interferon; Middle east respiratory syndrome; Pneumonia; Ribavirin

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; HYPERTENSIVE FACTOR; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE; OSELTAMIVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CRITICALLY ILL PATIENT; EXTRACORPOREAL OXYGENATION; FEMALE; FOLLOW UP; HIGH FREQUENCY OSCILLATION; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST RESPIRATORY SYNDROME; MORTALITY; OBSERVATIONAL STUDY; PLATELET COUNT; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SAUDI ARABIA; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; VIRAL CLEARANCE; BLOOD; CLINICAL TRIAL; CORONAVIRUS INFECTION; CRITICAL ILLNESS; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MULTICENTER STUDY; TREATMENT OUTCOME; VIRUS PNEUMONIA;

AGED; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTERFERON ALPHA-2; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PNEUMONIA, VIRAL; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SAUDI ARABIA; TREATMENT OUTCOME;

EID: 85083545281     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciz544     Document Type: Article

References (26)

1. Arabi YM, Balkhy HH, Hayden FG, et al. Middle East respiratory syndrome. N Engl J Med 2017; 376:584-94.
2. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 2013; 3:1686.
3. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19:1313-7.
4. Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013; 17:e792-8.
5. Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95:571-7.
6. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: A preliminary report of two cases. Antivir Ther 2015; 20:87-91.
7. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: An observational study. Int J Infect Dis 2014; 20:42-6.
8. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: A retrospective study. J Antimicrob Chemother 2015; 70:2129-32.
9. Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect Dis 2014; 14:1090-5.
10. Al Ghamdi M, Alghamdi KM, Ghandoora Y, et al. Treatment outcomes for patients with Middle Eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis 2016; 16:174.
11. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167:492-9.
12. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: Immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168:49-53.
13. Arabi YM, Shalhoub S, Al Omari A, et al. Effect of ribavirin and interferon on the outcome of critically ill patients with MERS. Am J Resp Crit Care Med 2017; 195:A6067.
14. Arabi YM, Al-Omari A, Mandourah Y, et al; Saudi Critical Care Trial Group. Critically ill patients with the Middle East respiratory syndrome: A multicenter retrospective cohort study. Crit Care Med 2017; 45:1683-95.
15. Corman VM, Muller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012; 17. pii:20334.
16. Arabi YM, Alothman A, Balkhy HH, et al; MIRACLE Trial Group. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): Study protocol for a randomized controlled trial. Trials 2018; 19:81.
17. International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Available at: Https://isarictghnorg/. Accessed 25 March 2016.
18. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26:1793-800.
19. Arabi YM, Mandourah Y, Al-Hameed F, et al; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018; 197:757-67.
20. Delaney JW, Pinto R, Long J, et al; Canadian Critical Care Trials Group H1N1 Collaborative. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit Care 2016; 20:75.
21. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-70.
22. Faries DE, Kadziola ZA. Analysis of longitudinal observational data using marginal structural models. In: Analysis of observational health care data using SAS. Cary, NC: SAS Institute Inc; 2010:211.
23. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-60.
24. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606-16.
25. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Trans Med 2017; 9. doi:10.1126/scitranslmed.aal3653.
26. Beigel JH, Voell J, Kumar P, et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: A phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis 2018; 18:410-8.